Procaps Group (Procaps Group) EV-to-EBIT : 5.48 (As of May. 08, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Procaps Group EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Procaps Group's Enterprise Value is $581.1 Mil. Procaps Group's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was $106.0 Mil. Therefore, Procaps Group's EV-to-EBIT for today is 5.48.

The historical rank and industry rank for Procaps Group's EV-to-EBIT or its related term are showing as below:

PROC' s EV-to-EBIT Range Over the Past 10 Years
Min: -269.83 Med: 9.18 Max: 165.83
Current: 5.48

During the past 4 years, the highest EV-to-EBIT of Procaps Group was 165.83. The lowest was -269.83. And the median was 9.18.

PROC's EV-to-EBIT is ranked better than
89.36% of 667 companies
in the Drug Manufacturers industry
Industry Median: 17.97 vs PROC: 5.48

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Procaps Group's Enterprise Value for the quarter that ended in Sep. 2023 was $671.6 Mil. Procaps Group's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was $106.0 Mil. Procaps Group's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was 15.78%.

Procaps Group EV-to-EBIT Historical Data

The historical data trend for Procaps Group's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Procaps Group EV-to-EBIT Chart

Procaps Group Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

EV-to-EBIT

-696.60

10.63

Procaps Group Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
EV-to-EBIT	Get a 7-Day Free Trial											40.90	10.63	11.17	6.25	6.34

Competitive Comparison of Procaps Group's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Procaps Group's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Procaps Group's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Procaps Group's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Procaps Group's EV-to-EBIT falls into.

Procaps Group EV-to-EBIT Calculation

Procaps Group's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	581.125	/	105.985
	=	5.48

Procaps Group's current Enterprise Value is $581.1 Mil.
Procaps Group's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $106.0 Mil.

Procaps Group (NAS:PROC) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Procaps Group's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Sep. 2023 )	=	EBIT	/	Enterprise Value (Q: Sep. 2023 )
	=	105.985	/	671.57988
	=	15.78 %

Procaps Group's Enterprise Value for the quarter that ended in Sep. 2023 was $671.6 Mil.
Procaps Group's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $106.0 Mil.

Procaps Group EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Procaps Group's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Procaps Group (Procaps Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Procaps Group SA (NAS:PROC) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

9X1:Germany

Address

9 Rue de Bitbourg, Luxembourg, LUX, L-1273

Website

https://www.procapsgroup.com

Procaps Group SA is a developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies. It develops, manufactures, and markets over-the-counter (OTC) and prescription drugs, nutritional supplements, and high-potency clinical solutions. The company's segment includes NextGel; Procaps Colombia; CAN; CASAND and Diabetrics. It generates maximum revenue from the Procaps Colombia segment.

Executives

Alexandre Weinstein Manieu	director, 10 percent owner	CHASHAM PLACE, FLAT 1, LONDON X0 SW1X 8HG
Ruben Minski	director, 10 percent owner, officer: Chief Executive Officer	9 RUE DE BITBOURG, C/O PROCAPS GROUP, S.A., LUXEMBOURG N4 L-1273
Jose Minski	director, 10 percent owner	9 RUE DE BITBOURG, C/O PROCAPS GROUP, S.A., LUXEMBOURG N4 L-1273
Sognatore Trust	10 percent owner	OFICINA 503A-02, EDIFICIO QUANTUM, (500) RUTA 8 KM. 17.500 ZONAMERICA, MONTEVIDEO X3 91600
Simphony Trust	10 percent owner	29 BANCROFT MILLS ROAD, WILMINGTON DE 19806
Deseja Trust	10 percent owner	29 BANCROFT MILLS ROAD, WILMINGTON DE 19806
Hoche Partners Pharma Holding S.a.	10 percent owner	3A VAL SAINTE CROIX, LUXEMBOURG N4 L-1371